Skip to main content
letter
. 2021 Dec 9;5(23):5344–5348. doi: 10.1182/bloodadvances.2021005020

Figure 1.

Figure 1.

Ferritin, CRP, and treatment over time in patients who developed macrophage activation-like syndrome (MAS-L) following CAR T-cell therapy. Ferritin (red), C-reactive protein (CRP) (blue), and administration of tocilizumab (green triangle), systemic steroids (purple triangle), and/or anakinra (yellow) over time for the 12 patients who developed MAS-L.